한글목차

세계 mRNA 의약품 시장 규모는 2023년 330억 달러에서 예측 기간 동안 -8.6%의 CAGR을 기록하며 2028년 말에는 210억 달러 규모로 감소할 것으로 예상됩니다.

COVID 백신 부문은 2023년 330억 달러에서 -12.5%의 CAGR로 2028년 169억 달러로 감소할 것으로 예측됩니다. 반면, 비(非)COVID 의약품 및 백신 부문은 예측 기간 동안 94.7%의 CAGR을 기록하며 2025년 5억 6,000만 달러, 2028년 41억 달러로 성장할 것으로 예상됩니다.

세계의 mRNA 의약품 시장을 조사했으며, 시장 및 의약품 개요와 배경, 시장 영향요인 및 시장 기회 분석, 대상 질환 및 장애, 시장 규모 추이 및 예측, 각 부문별·지역별 상세 분석, 기술 및 특허 동향, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 요약과 하이라이트

• 시장 전망
• 시장 요약

제3장 시장 개요

• RNA 의약품의 진화
• RNA 의약품의 역사
• RNA 의약품의 개발과 그 종류
• DNA 의약품 vs RNA 의약품
• RNA 의약품의 임상적 필요성
• 질병 인구와 경제적 부담 증가
• 기존 의약품의 한계
• 생물제제의 치료상 한계
• 만성질환 관리가 불충분
• 희귀질환에 대한 치료 한정성
• RNA 의약품
• 의약품으로서의 안티센스 올리고뉴클레오티드(ASO)
• 의약품으로서의 저분자 간섭 RNA(siRNA)
• 의약품으로서의 miRNA
• 의약품으로서의 압타머
• 의약품으로서의 mRNA
• RNA 기반 바이오의약품 제조
• 크로마토그래피 정제 절차
• RNA 의약품의 제공
• 폴리머 결합/화학 변성
• 캡슐화
• 지질 기반 나노입자
• 폴리머 나노재료
• 실리카 나노입자
• 탄소 및 금 나노재료
• GalNAc
• 시설 및 병원 기반 RNA 의약품
• RNA 의약품 시장에 대한 규제의 영향
• COVID-19의 영향

제4장 시장 역학

• 시장 역학
• 성장 촉진요인
• 성장 억제요인
• 기회

제5장 대상이 되는 질환 및 장애

• mRNA 의약품의 일반적인 질환과 장애 개요
• 암
• 감염증
• 순환기질환
• 생활습관병
• 호흡기질환
• 근골격계 질환
• 위장장애
• 비뇨기과 질환
• 신장질환
• 면역질환
• 신경학적 장애
• 희귀질환
• 기타 질환
• 흡연과 관련 질환
• 감염증 : COVID-19 팬데믹과 mRNA 의약품
• 만성질환 : mRNA 의약품의 시야를 확대
• 희귀질환의 미충족 수요 : mRNA 의약품
• 노화, 성별, 질병 발증
• 세계의 인구통계
• 미국의 인구통계
• 유럽의 인구통계
• 일본의 인구통계

제6장 파이프라인과 임상시험 분석

• mRNA 백신
• mRNA 의약품
• 임상시험 분석

제7장 시장 내역 : 제품별

• mRNA COVID 백신의 작용기서
• 가장 진보된 3가지 mRNA 백신

제8장 시장 내역 : 지역별

• 북미
• 캐나다
• 유럽
• 아시아태평양
• 일본
• 한국
• 중국
• 인도
• 호주
• 기타 지역

제9장 새로운 기술과 개발

• 개요
• 나노입자
• 변성 mRNA
• 자동 mRNA 합성 키트
• 바이오 플랫폼

제10장 특허 분석

• 특허 분석
• mRNA 출원 공개

제11장 M&A 및 벤처 자금 조달 전망

제12장 경쟁 정보

제13장 기업 개요

• ARCTUR U.S. THERAPEUTICS INC.
• BIONTECH SE
• CUREVAC N.V.
• GENNOVA BIOPHARMACEUTICALS LTD.
• MERCK KGAA
• MODERNA INC.
• NUTCRACKER THERAPEUTICS
• OMEGA THERAPEUTICS INC.
• STRAND THERAPEUTICS
• VAXESS TECHNOLOGIES INC.

영문목차

Highlights:

The global market for mRNA therapeutics is expected to decline from $33 billion in 2023 to $21 billion by the end of 2028, at a compound annual growth rate (CAGR) of -8.6% during the forecast period of 2023-2028.

The COVID vaccines segment of the mRNA therapeutics market is expected to decline from $33 billion in 2023 to $16.9 billion by 2028, at a CAGR of -12.5% during the forecast period of 2023-2028.

The non-COVID therapeutics and vaccines segment of the mRNA therapeutics market is expected to grow from $560 million in 2025 to $4.1 billion by 2028, at a CAGR of 94.7% during the forecast period of 2023-2028.

Report Scope:

This report focuses on the mRNA therapeutics market. This reports include the types of mRNA and their application in therapy. Also, the report focuses on the patent analysis and clinical trial analysis of mRNA. The report also portrays the trends and dynamics affecting the market during the study period. The study covers market projections through 2028 and profiles major market players.

By geography, the market is segregated into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The market is estimated through 2028.

BCC Research also summarizes the main industry acquisitions and strategic alliances from January 2020 through December 2022 and identifies the trends in this activity.

Report Includes:

• 37 data tables and 27 additional tables
• An overview of the global market related to mRNA therapeutics
• In-depth analysis of global market trends, featuring historical revenue data for 2021 and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
• Evaluation of the current market and revenue growth prospects specific to mRNA therapeutics, accompanied by a market share analysis by therapeutic type and geographical region
• Coverage of the pandemic threats, therapeutic developments, and new technologies in the market
• Discussion of the advantages of mRNA over protein- and DNA-based delivery systems, demographic and economic trends, and outlook for the mRNA therapeutics market
• Information on prophylactic vaccines, vaccine discovery and development, and R&D activities
• Analysis of the various therapeutics as well as promising vaccines intended for the prevention and treatment of chronic and infectious diseases
• Assessment of regulatory structure, pricing and reimbursement scenarios, the pipeline for new molecules and therapeutics
• Market share analysis of the key companies and mergers & acquisitions, joint ventures, collaborations, and partnerships
• Profiles of leading market participants

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in This Update?
• Methodology
• Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Evolution of RNA Therapeutics
• History of RNA Therapeutics
• Development of RNA Therapeutics and Types
• DNA Therapeutics vs. RNA Therapeutics
• Clinical Need for RNA Therapeutics
• Increasing Disease Population and Economic Burden
• Limitations of Traditional Therapeutics
• Therapeutic Limitations of Biologics
• Poor Management of Chronic Diseases
• Limited Treatment for Rare Diseases
• RNA Therapeutics
• Antisense Oligonucleotide (ASO) as Therapeutics
• Small Interfering RNA (siRNA) as Therapeutics
• miRNA as Therapeutics
• Aptamers as Therapeutics
• mRNA as Therapeutics
• Manufacturing RNA-Based Biopharmaceuticals
• Chromatographic Purification Steps
• Delivery of RNA Therapeutics
• Polymer Conjugation/Chemical Modification
• Encapsulation
• Lipid-Based Nanoparticles
• Polymer Nanomaterials
• Silica Nanoparticles
• Carbon and Gold Nanomaterials
• GalNAc
• Institution and Hospital-Based RNA Therapeutics
• Regulatory Influence on the Market for RNA Therapeutics
• Impact of COVID-19

Chapter 4 Market Dynamics

• Market Dynamics
• Drivers
• Restraints
• Opportunities

Chapter 5 Target Disease and Disorders

• Overview of Common Diseases and Disorders for mRNA Therapeutics
• Cancer
• Infectious Diseases
• Cardiovascular Disease
• Lifestyle Disorders
• Respiratory Disorders
• Musculoskeletal Disorders
• Gastrointestinal Disorders
• Urology Disorders
• Nephrology Disorders
• Immune Disorders
• Neurological Disorders
• Rare Diseases
• Other Disorders
• Tobacco Smoking and Associated Diseases
• Infectious Diseases: COVID-19 Pandemic and mRNA Therapeutics
• Chronic Diseases: Expanding Horizon for mRNA Therapeutics
• Unmet Needs of Rare Diseases: mRNA Therapeutics
• Aging, Gender and Onset of Diseases
• Global Demographics
• U.S. Demographics
• European Demographics
• Japanese Demographics

Chapter 6 Pipeline and Clinical Trial Analysis

• mRNA Vaccines
• mRNA Therapeutics
• Clinical Trial Analysis

Chapter 7 Market Breakdown by Product

• Mechanism of Action of mRNA COVID Vaccines
• Three Most-Advanced mRNA Vaccines

Chapter 8 Market Breakdown by Region

• North America
• Canada
• Europe
• Asia-Pacific
• Japan
• South Korea
• China
• India
• Australia
• RoW

Chapter 9 Emerging Technologies and Developments

• Overview
• Nanoparticles
• Modified mRNA
• Automated mRNA Synthesis Kits
• Bio Platforms

Chapter 10 Patent Analysis

• Patent Analysis
• mRNA Publication

Chapter 11 Outlook for Mergers & Acquisitions, and Venture Funding

Chapter 12 Competitive Intelligence

Chapter 13 Company Profiles

• ARCTUR U.S. THERAPEUTICS INC.
• BIONTECH SE
• CUREVAC N.V.
• GENNOVA BIOPHARMACEUTICALS LTD.
• MERCK KGAA
• MODERNA INC.
• NUTCRACKER THERAPEUTICS
• OMEGA THERAPEUTICS INC.
• STRAND THERAPEUTICS
• VAXESS TECHNOLOGIES INC.